[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL150530A0 - Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses - Google Patents

Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses

Info

Publication number
IL150530A0
IL150530A0 IL15053001A IL15053001A IL150530A0 IL 150530 A0 IL150530 A0 IL 150530A0 IL 15053001 A IL15053001 A IL 15053001A IL 15053001 A IL15053001 A IL 15053001A IL 150530 A0 IL150530 A0 IL 150530A0
Authority
IL
Israel
Prior art keywords
dihydro
therapeutic uses
amine derivatives
triazine amine
triazine
Prior art date
Application number
IL15053001A
Other languages
English (en)
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8846333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL150530(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipha filed Critical Lipha
Publication of IL150530A0 publication Critical patent/IL150530A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12Antidiuretics, e.g. drugs for diabetes insipidus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/10Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40Nitrogen atoms
    • C07D251/48Two nitrogen atoms
    • C07D251/52Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D251/00Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/72Heterocyclic compounds containing 1,3,5-triazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15053001A 2000-01-26 2001-01-25 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses IL150530A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0000996A FR2804113B1 (fr) 2000-01-26 2000-01-26 Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
PCT/FR2001/000241 WO2001055122A1 (fr) 2000-01-26 2001-01-25 Derives amines de dihydro-1,3,5-triazine et leurs applications en therapeutique

Publications (1)

Publication Number Publication Date
IL150530A0 true IL150530A0 (en) 2003-02-12

Family

ID=8846333

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15053001A IL150530A0 (en) 2000-01-26 2001-01-25 Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses

Country Status (37)

Country Link
US (4) US7034021B2 (pl)
EP (1) EP1250328B2 (pl)
JP (1) JP4926357B2 (pl)
KR (1) KR100722438B1 (pl)
CN (1) CN1195743C (pl)
AP (1) AP2002002578A0 (pl)
AR (1) AR027293A1 (pl)
AT (1) ATE332294T1 (pl)
AU (1) AU782307B2 (pl)
BG (1) BG106933A (pl)
BR (1) BRPI0107815B8 (pl)
CA (1) CA2397636C (pl)
CY (1) CY1105344T1 (pl)
CZ (1) CZ303445B6 (pl)
DE (1) DE60121294T3 (pl)
DK (1) DK1250328T4 (pl)
EA (1) EA005378B1 (pl)
EE (1) EE05003B1 (pl)
ES (1) ES2267715T5 (pl)
FR (1) FR2804113B1 (pl)
HK (1) HK1050529A1 (pl)
HR (1) HRP20020625A2 (pl)
HU (1) HU230790B1 (pl)
IL (1) IL150530A0 (pl)
IS (1) IS6467A (pl)
MA (1) MA25650A1 (pl)
MX (1) MXPA02007232A (pl)
NO (1) NO20023532L (pl)
OA (1) OA12165A (pl)
PL (1) PL205345B1 (pl)
PT (1) PT1250328E (pl)
SI (1) SI1250328T2 (pl)
SK (1) SK287647B6 (pl)
TN (1) TNSN01012A1 (pl)
WO (1) WO2001055122A1 (pl)
YU (1) YU55602A (pl)
ZA (1) ZA200205314B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
MXPA05006450A (es) * 2002-12-17 2005-08-19 Hamari Chemicals Ltd Nuevo derivado de 2,4-diamino-1,3,5-triazina.
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
DE602006018456D1 (de) * 2005-06-14 2011-01-05 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
FR2896160B1 (fr) * 2006-01-13 2008-04-25 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agonistes du ppar alpha.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896161B1 (fr) * 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896158B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
DE102007054416A1 (de) 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) * 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
MX2010012626A (es) * 2008-05-20 2011-02-22 Merck Sharp & Dohme Produccion eficiente de proteinas heterologas utilizando inhibidores de manosil transferasa.
CA2725011A1 (en) * 2008-05-23 2009-11-26 Poxel Sas Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
JPWO2010024225A1 (ja) * 2008-08-25 2012-01-26 浜理薬品工業株式会社 新規ジヒドロトリアジン誘導体
ES2573266T3 (es) * 2008-12-12 2016-06-06 Poxel Compuestos de tetrahidrotriazina para tratar enfermedades relacionadas con la actividad de AMPK
ES2530223T3 (es) * 2008-12-12 2015-02-27 Poxel S.A.S. Combinación de insulina con derivados de triazina y su uso para tratar la diabetes
WO2010103040A1 (en) 2009-03-10 2010-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) 5'-adenosine monophosphate-activated protein kinase (ampk) activators for treating pulmonary hypertension
WO2010109015A1 (en) 2009-03-26 2010-09-30 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
FR2948026B1 (fr) * 2009-07-17 2011-12-02 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine
FR2948028B1 (fr) 2009-07-17 2011-12-02 Merck Sante Sas Association d'un inhibiteur de l'echangeur sodium-proton et d'un derive amine de dihydro-1,3,5-triazine
ES2577930T3 (es) * 2010-06-09 2016-07-19 Poxel Derivados de triazina para retrasar el inicio de la diabetes tipo 1
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第2型糖尿病之治療
EA022300B1 (ru) 2010-12-01 2015-12-30 Поксел Разделение энантиомеров 2-амино-3,6-дигидро-4-диметиламино-6-метил-1,3,5-триазина с использованием винной кислоты
RU2658819C2 (ru) * 2016-05-26 2018-06-25 федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный технический университет" Применение гетероциклических гидразонов в качестве средств, обладающих антигликирующей активностью
FR3068601B1 (fr) 2017-07-05 2021-02-19 Eric Joseph Marie Fulgence Janin Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire
BR112020006472A2 (pt) 2017-10-02 2020-10-06 Poxel método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep)
MX2020013210A (es) * 2018-06-06 2021-02-26 Metavant Sciences Gmbh Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica.
KR20210003786A (ko) 2018-06-14 2021-01-12 폭셀 당뇨병의 치료에서 사용하기 위한 트리아진 유도체를 포함하는 필름 코팅정
WO2022152138A1 (zh) * 2021-01-15 2022-07-21 中国医药研究开发中心有限公司 稠和杂环类化合物及其制备方法和医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) * 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
US3286366A (en) * 1964-10-26 1966-11-22 Seligman Monroe Apparatus for freeze drying products in small containers
JPS4856692A (pl) * 1971-11-19 1973-08-09
JPS4864088A (pl) * 1971-12-13 1973-09-05
JPS5414986A (en) * 1977-07-01 1979-02-03 Taiho Pharmaceutical Co Ltd Production of dihydrooss triazine derivative
US4246408A (en) * 1979-03-08 1981-01-20 Icn Pharmaceuticals Imidazo[1,2-a]-s-triazine
GR74944B (pl) * 1980-07-02 1984-07-12 Merck & Co Inc
US4277602A (en) * 1980-07-02 1981-07-07 Merck & Co., Inc. 3-Amino-5-substituted-6-halo-N-(3,4-dihydro-6-substituted-1,3,5-truazin-2-yl)2-pyrazinecarboxamides
US4576945A (en) * 1982-10-26 1986-03-18 Sanders Mark E Hexaalkylmelamine-amino-oxy compounds
JPS6141915A (ja) 1984-08-03 1986-02-28 Omron Tateisi Electronics Co 測距装置
DD257010A1 (de) * 1987-01-13 1988-06-01 Berlin Chemie Veb Ergotrope mittel
DE3801113A1 (de) * 1987-07-23 1989-02-02 Bayer Ag Substituierte triazine
IT1244870B (it) * 1990-09-11 1994-09-12 Ministero Dall Uni E Della Ric Composti ammelinici
DE19641692A1 (de) * 1996-10-10 1998-04-23 Bayer Ag Substituierte 2,4-Diamino-1,3,5-triazine
EP1037886B1 (en) * 1997-12-12 2003-05-02 Abbott Laboratories Triazine angiogenesis inhibitors
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique

Also Published As

Publication number Publication date
KR20020075395A (ko) 2002-10-04
US20080108591A1 (en) 2008-05-08
OA12165A (fr) 2006-05-08
CA2397636A1 (fr) 2001-08-02
SK287647B6 (sk) 2011-05-06
AP2002002578A0 (en) 2002-09-30
HK1050529A1 (en) 2003-06-27
CN1404472A (zh) 2003-03-19
PL205345B1 (pl) 2010-04-30
HU230790B1 (en) 2018-05-02
DK1250328T4 (da) 2010-06-28
AU782307B2 (en) 2005-07-21
DE60121294T3 (de) 2010-09-23
CZ20022462A3 (cs) 2003-04-16
EE05003B1 (et) 2008-04-15
CY1105344T1 (el) 2010-03-03
ZA200205314B (en) 2005-07-27
SK9762002A3 (en) 2003-05-02
HUP0204087A3 (en) 2006-01-30
JP2003520858A (ja) 2003-07-08
EA005378B1 (ru) 2005-02-24
DE60121294T2 (de) 2007-08-30
CA2397636C (fr) 2010-04-06
FR2804113B1 (fr) 2004-06-18
EP1250328B1 (fr) 2006-07-05
HRP20020625A2 (en) 2003-10-31
PL357191A1 (pl) 2004-07-26
BRPI0107815B1 (pt) 2017-08-29
US20050165022A1 (en) 2005-07-28
IS6467A (is) 2002-07-11
US7452883B2 (en) 2008-11-18
BRPI0107815B8 (pt) 2021-05-25
CZ303445B6 (cs) 2012-09-19
ATE332294T1 (de) 2006-07-15
FR2804113A1 (fr) 2001-07-27
EP1250328A1 (fr) 2002-10-23
NO20023532D0 (no) 2002-07-24
JP4926357B2 (ja) 2012-05-09
ES2267715T5 (es) 2010-06-10
CN1195743C (zh) 2005-04-06
BG106933A (en) 2003-07-31
AU3560301A (en) 2001-08-07
NO20023532L (no) 2002-09-25
US20030109530A1 (en) 2003-06-12
EE200200414A (et) 2003-10-15
PT1250328E (pt) 2006-10-31
SI1250328T2 (sl) 2010-09-30
EA200200790A1 (ru) 2003-02-27
US7767676B2 (en) 2010-08-03
WO2001055122A1 (fr) 2001-08-02
US20080108619A1 (en) 2008-05-08
MXPA02007232A (es) 2003-10-15
EP1250328B2 (fr) 2010-04-21
SI1250328T1 (sl) 2006-10-31
YU55602A (sh) 2005-03-15
US7034021B2 (en) 2006-04-25
MA25650A1 (fr) 2002-12-31
HUP0204087A2 (hu) 2003-04-28
KR100722438B1 (ko) 2007-05-29
AR027293A1 (es) 2003-03-19
DE60121294D1 (de) 2006-08-17
BR0107815A (pt) 2002-10-29
DK1250328T3 (da) 2006-10-30
ES2267715T3 (es) 2007-03-16
TNSN01012A1 (fr) 2005-11-10

Similar Documents

Publication Publication Date Title
IL150530A0 (en) Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
HUP0400708A3 (en) Substituted 1,3,5-triazine and pyrimidine derivatives, their use and pharmaceutical compositions containing them
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
HK1048999A1 (zh) 氮雜䓬吲衍生物,它們的製備和應用
HK1048636A1 (en) N-(indolcarbonyl-)piperazin derivatives
AU2002359126A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
HK1081954A1 (en) Novel 1,4-diazabicycloalkane derivatives, their preparation and use
AU2002359123A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
NZ513917A (en) 1-aryl-1,3,5-triazine-4-thione-2,6-diones, production thereof and use thereof as herbicides
IL154675A0 (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
HUP0600238A3 (en) Benzothiazole- and benzoxazole-4,7-dione derivatives and their use
HUP0102832A3 (en) Herbicidal substituted 2,4-diamino-1,3,5-triazine derivatives, preparation and use thereof
HUP0202377A2 (en) N-substituted perhydrodiazines, preparation and use thereof
PL365342A1 (pl) Pochodne mikanolidu, ich wytwarzanie i zastosowania terapeutyczne
HUP0103358A3 (en) N-substituted azabicycloheptane derivatives, production and use thereof
AU7815201A (en) Synthetic salicylihalamides, apicularens and derivatives thereof
AU7422100A (en) Alkyl-amino-1,3,5-triazines and their use as herbicides
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors
HUP0103099A3 (en) N-substituted azabicycloheptane derivatives, production and use thereof
SI1105388T1 (en) N-substituted azabicycloheptane derivatives, production and use thereof
SI1104419T1 (en) N-substituted azabicycloheptane derivatives, production and use thereof
GB0012376D0 (en) 3,4,5-tricyanophenyl derivatives
ZA200002368B (en) Synthesis of 5,5'-Diformyl-2,2'Difuran and Derivatives thereof.
ZA200204266B (en) Arylamine derivatives and their use as anti-telomerase agent.
PL353421A1 (pl) Nowe związki, pochodne symetrycznej 1,3,5-triazyny